Since 2007, the guideline development process within the World Health Organization (WHO) has
been overseen by the WHO Guidelines Review Committee (GRC), which follows internationally
recognized standards such as the GRADE (Grading of Recommendations Assessment, Development
and Evaluation) approach, to su...
Las cepas del bacilo tuberculoso con farmacorresistencia (TB-DR) son más difíciles de tratar que las
farmacosensibles y amenazan el progreso mundial hacia los objetivos establecidos por la Estrategia Fin de
la TB, de la Organización Mundial de la Salud (OMS). Por lo tanto, existe una necesidad imperio...
Tuberculosis (TB) strains with drug resistance (DR-TB) are more difficult to treat than drug-susceptible ones, and threaten global progress towards the targets set by the End TB Strategy of the World Health Organization (WHO). There is thus a critical need for evidence-based policy recommendations on the...
Isoniazid (H) is one of the most important first-line medicines for the treatment of active
tuberculosis (TB) and latent TB infection (LTBI), with high bactericidal activity and a good safety profile. The emergence of TB strains resistant to isoniazid threaten to reduce the effectiveness of TB treatment....
The present guideline update aims to use the best available evidence on the treatment of drug-susceptible TB, as well as on interventions to ensure adequate patient care and support, in order to inform policy decisions made in these technical areas by national TB control programme managers, national poli...
This document provides a summary of the evidence and recommendations for the use of SL-LPA for the detection of mutations associated with resistance to fluoroquinolones and SLID in patients with RR-TB and/or MDR-TB. The objectives of this policy guidance are to assess and compare the diagnostic accuracy ...
Tuberculose multirésistante/diagnostic,
Antibiotiques antituberculeux/pharmacologie,
Techniques de sonde moléculaire,
Tests de sensibilité microbienne,
Fluoroquinolones/usage thérapeutique,
Résistance bactérienne aux médicaments/génétique,
Génotype,
Mutation,
Tuberculose multirésistante/génétique,
Mycobacterium tuberculosis/effets des médicaments et des substances chimiques,
Mycobacterium tuberculosis/génétique
Tuberculosis (TB) remains a large-scale public health problem. Key global priorities for TB care and control include improving case-detection and detecting cases earlier, including cases of smear-negative disease. This document updates existing WHO policy on the use of molecular LPAs for detecting MTBC a...
The specific objectives were to evaluate the harms to benefits ratio of delamanid in combination with the currently recommended MDR-TB treatment regimen in children. Based on this evaluation, to develop recommendations on the use of delamanid as part of WHO-recommended longer MDR-TB treatment regimens, a...
In November 2015, the World Health Organization (WHO) convened a meeting of a Guideline Development Group (GDG) for the update of policy recommendations on the treatment of drug-resistant TB. The GDG was composed of a multidisciplinary group of tuberculosis (TB) and drug-resistant TB experts external to ...
The aim of this guidance is to provide the interim principles that should guide the use of delamanid in conjunction with WHO-recommended MDR-TB treatment. It also specifies the essential treatment and management conditions for use of this drug, in particular the patient's eligibility criteria and safety ...
